Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well. In a couple of ...

In a review, researchers outlined the safety and efficacy of erenumab, the only monoclonal antibody built to interact with the calcitonin gene related peptide (CGRP) receptor rather than the CGRP ...

People who have tried unsuccessfully to prevent migraine with other treatments may find relief with a new drug, according to a preliminary study released Tuesday. Erenumab is part of new class of ...

Safety profile similar to other trials, with 6 in 10 sustaining medication overuse headache remission over 6 months. HealthDay News — Monthly use of erenumab injections (140mg) is safe and effective ...

Please provide your email address to receive an email when new articles are posted on . New real-world data show a monthly self-injection of erenumab, a preventive migraine treatment, reduced migraine ...

Erenumab treatment has been associated with reductions in migraine frequency and improvements in health-related quality of life that were maintained for at least 5 years, according to the results of ...

SAN FRANCISCO — The fully humanized monoclonal antibody erenumab (Aimovig, Novartis/Amgen) is safe and effective in preventing refractory episodic migraine, new research suggests. Results of a ...

Amgen announced positive top-line results from their Phase 3 trial ARISE, evaluating erenumab (AMG 334) for safety and efficacy in preventing migraines. Amgen announced positive top-line results from ...

Please provide your email address to receive an email when new articles are posted on . A 52-week open label extension of a previous 12-week double-blind treatment study showed sustained efficacy and ...

Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and ...